Tolerability of SC Amivantamab Plus Lazertinib in Frontline EGFR+ NSCLC

Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from the PALOMA-2 trial. She explains that the data thus far have shown comparable discontinuation rates related to adverse events for the SC regimen compared with what has been observed with intravenous amivantamab regimens in prior studies.